JNJ Price Prediction Next Week
Technical Analysis: Based on the latest data, JNJ shows strong bullish momentum with RSI(14) at 71.58 and Stochastic %K(14) at 94.03, both indicating overbought conditions. The stock is trading above all major moving averages (5,10,20,60,200-day SMAs), confirming the upward trend.
Price Targets for Next Week:
- Support levels: $157.50 (Fibonacci pivot), $153.21 (S1)
- Resistance levels: $161.79 (R1), $164.43 (R2)
News Sentiment Analysis: Recent positive catalysts include:
- JNJ ranks 9th among best-performing Dow stocks in 2025 with YTD return of 8.42%
- Successful late-stage trial results for TREMFYA in treating ulcerative colitis
- Guggenheim analyst raised price target to $166 from $162
Price Prediction for Next Week: Given the technical indicators and positive news flow, JNJ is likely to test the R1 resistance at $161.79. However, the overbought conditions suggest potential for a short-term pullback. The most probable scenario is:
- Monday-Tuesday: Slight pullback to $157-158 range due to profit-taking
- Mid-week: Consolidation around $158-160
- End of week: Push toward $161-162 if broader market remains supportive
Trading Recommendation: SELL Despite positive fundamentals, the extremely overbought technical readings (RSI>70, Stochastic>90) suggest high probability of a short-term pullback. Traders should consider taking profits at current levels and wait for a better entry point around the Fibonacci pivot ($157.50) or S1 ($153.21) levels.
JNJ Similar Chart Price Prediction
The price of JNJ is predicted to go up 0.29%, based on the high correlation periods with MLGO. The similarity of these two price pattern on the periods is 98%.
JNJ
MLGO
Up: 0.29%Similarity: 98%
JNJ Revenue Forecast
JNJ EPS Forecast
JNJ FAQs
What is bull’s view on JNJ?
What is bear's view on JNJ?
What is JNJ revenue forecast for next quarter？
What is JNJ eps forecast for next quarter？
JNJ VS S&P500
The majority of J&J's near-term patent losses are for products that are hard to manufacture, which should reduce the intensity of generic competition.
Diverse healthcare segments help insulate J&J from downturns in the overall economy, offering a defensive growth opportunity with a steady and likely growing dividend.
Several of J&J's key next-generation pipeline drugs are specialty drugs that tend to carry strong pricing power as well as lower regulatory hurdles for approval.
JNJ Analyst's Forecast
Matt Miksic
Barclays
Hold
2025-01-28
Price Target
$159 → $166
Upside
+10.39%
Barclays lowered the firm's price target on Johnson & Johnson to $159 from $160 and keeps an Equal Weight rating on the shares. The firm says its 2025 medical technology outlook "hinges heavily" on factors like inflation, interest rates, surgical volumes and a range of policy actions under consideration by the new U.S. administration. It remains "generally bullish" on the fundamentals of most end markets in its coverage universe. Utilization appears to be ending the year at a "healthy clip," and unemployment remains at historic lows, which is favorable for continued healthcare utilization and surgical procedure growth, the analyst tells investors in a research note. However, Barclays believes macro factors could have greater impact on stock performance than fundamentals, at least in the very near term.
Shagun Singh
RBC Capital
Buy
2025-01-23
Price Target
$181
Upside
+23.43%
Terence Flynn
Morgan Stanley
Hold
2025-01-23
Price Target
$175 → $163
Upside
+11.16%
